Anhui Huaheng Biotechnology Management
Management criteria checks 4/4
Anhui Huaheng Biotechnology's CEO is Henghua Guo, appointed in Nov 2013, has a tenure of 11.08 years. directly owns 23.04% of the company’s shares, worth CN¥1.76B. The average tenure of the management team and the board of directors is 7.2 years and 8.9 years respectively.
Key information
Henghua Guo
Chief executive officer
CN¥1.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 11.1yrs |
| CEO ownership | 23.0% |
| Management average tenure | 7.2yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Analysts Just Cut Their EPS Forecasts Substantially
Dec 20
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Soars 35% But It's A Story Of Risk Vs Reward
Oct 21Here's Why We Think Anhui Huaheng Biotechnology (SHSE:688639) Is Well Worth Watching
Oct 14Slammed 29% Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Screens Well Here But There Might Be A Catch
Sep 05Anhui Huaheng Biotechnology's (SHSE:688639) Profits Appear To Have Quality Issues
Sep 03Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Analysts Just Cut Their EPS Forecasts Substantially
Sep 02Many Would Be Envious Of Anhui Huaheng Biotechnology's (SHSE:688639) Excellent Returns On Capital
Aug 20Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jul 22Anhui Huaheng Biotechnology Co., Ltd.'s (SHSE:688639) Intrinsic Value Is Potentially 43% Above Its Share Price
Jul 12Is Anhui Huaheng Biotechnology (SHSE:688639) Using Too Much Debt?
Jun 21Take Care Before Jumping Onto Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Even Though It's 27% Cheaper
Jun 05We Ran A Stock Scan For Earnings Growth And Anhui Huaheng Biotechnology (SHSE:688639) Passed With Ease
May 12Earnings Report: Anhui Huaheng Biotechnology Co., Ltd. Missed Revenue Estimates By 37%
Apr 23Anhui Huaheng Biotechnology Co., Ltd.'s (SHSE:688639) Business Is Trailing The Market But Its Shares Aren't
Mar 18CEO
Henghua Guo (60 yo)
11.1yrs
Tenure
CN¥1,026,000
Compensation
Ms. Henghua Guo serves as Chairman of the Board and General Manager at Anhui Huaheng Biotechnology Co., Ltd., since November 2013.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 11.1yrs | CN¥1.03m | 23.04% CN¥ 1.8b | |
| CFO, Deputy GM | 8.9yrs | CN¥1.09m | 1.1% CN¥ 83.8m | |
| Chief Scientist & Director | no data | CN¥258.90k | 4.8% CN¥ 365.9m | |
| Deputy GM & Director | 3.3yrs | CN¥1.69m | 0.094% CN¥ 7.1m | |
| Deputy GM & Director | 11.1yrs | CN¥976.70k | 2.27% CN¥ 172.9m | |
| Deputy General Manager | 11.2yrs | CN¥468.00k | 0.44% CN¥ 33.5m | |
| Project Manager of MA | 2.3yrs | no data | 0.013% CN¥ 987.0k | |
| Deputy Manager of Technology Department of Qinhuangdao | 2.6yrs | no data | 0.014% CN¥ 1.1m | |
| Manager of Technical Department of Bayannaoer | 5.4yrs | no data | 0.012% CN¥ 914.5k |
7.2yrs
Average Tenure
43yo
Average Age
Experienced Management: 688639's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 11.1yrs | CN¥1.03m | 23.04% CN¥ 1.8b | |
| CFO, Deputy GM | 8.9yrs | CN¥1.09m | 1.1% CN¥ 83.8m | |
| Chief Scientist & Director | 11.1yrs | CN¥258.90k | 4.8% CN¥ 365.9m | |
| Deputy GM & Director | 3.3yrs | CN¥1.69m | 0.094% CN¥ 7.1m | |
| Deputy GM & Director | 11.1yrs | CN¥976.70k | 2.27% CN¥ 172.9m | |
| Independent Director | 5.3yrs | CN¥100.00k | no data | |
| Independent Director | 2.5yrs | CN¥100.00k | no data | |
| Director | 11.1yrs | no data | 2.22% CN¥ 169.0m | |
| Chairman of the Board of Supervisors | 5.7yrs | no data | 0.39% CN¥ 30.0m |
8.9yrs
Average Tenure
51yo
Average Age
Experienced Board: 688639's board of directors are considered experienced (8.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 06:11 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anhui Huaheng Biotechnology Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tianhe Wang | China International Capital Corporation Limited |
| Feifei Xu | China Merchants Securities Co. Ltd. |
| Chao Li | Citic Securities Co., Ltd. |